ClinicalTrials.gg
CompletedNCT03915496JADE MOAUpdated Feb 8, 2023Results posted

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis

A Phase 2 interventional study of PF-04965842 200 mg and PF-04965842 100 mg in Atopic Dermatitis, sponsored by Pfizer. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing abrocitinib in Dermatitis, Atopic — 5 open to participants now, 5 under way, 2 of them phase 3. abrocitinib · Dermatitis, Atopic.

Enrollment
15th of 20
46 · median 150
Started
2020
with 1 other
Phase 2
4 of 20
1 open now
Registered
10th of 20
by date
Lead sponsor
15 of 20
Pfizer

Among the 20 studies testing abrocitinib in Dermatitis, Atopic, this one is the 15th largest by enrollment, is one of 2 that started in 2020, is one of 4 in phase 2, and was the 10th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

5 of the 20 studies testing abrocitinib in Dermatitis, Atopic are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About abrocitinib

abrocitinib: first FDA approval 2022 (CIBINQO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing abrocitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

B7451037 is a randomized, double-blind, placebo-controlled, parallel-group, Phase 2a study to investigate the mechanism of action of PF-04965842 by correlating efficacy outcomes with changes from baseline in key skin and blood biomarkers in adult participants at least 18 years of age with moderate-to-severe atopic dermatitis. Participants will be screened within 28 days prior to the first dose of study intervention to confirm eligibility. A total of approximately 51 participants will be randomized in a 1:1:1 ratio to receive PF-04965842 200 mg once daily (QD), PF004965842 100 mg QD, or matching placebo QD for 12 weeks. At the end of the 12-week study treatment, qualified participants will have the option to enter the long-term extension study B7451015 (NCT03422822). Participants discontinuing early from this study will undergo a 4-week off-treatment follow-up period.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • atopic dermatitis
  • atopic eczema
  • eczema
  • JAK
  • janus kinase
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of chronic moderate-to-severe atopic dermatitis (AD) for at least 1 year
  • Recent history of inadequate response to medicated topical therapy for AD or required systemic therapy to control disease
  • Moderate-to-severe AD defined as affected BSA at least 10%, IGA at least 3, EASI at least 16, Peak Pruritus NRS at least 4

Exclusion criteria

Exclusion Criteria:

  • A current or past medical history of conditions associated with thrombocytopenia, coagulopathy, or dysfunction
  • Currently have active forms of other inflammatory skin diseases, i.e. not AD, or have evidence of skin conditions (e.g. psoriasis, seborrheic dermatitis, lupus) at the time of Day 1 that would interfere with evaluation of AD or response to treatment
  • Participants who have received prior treatment with any systemic JAK inhibitors
  • Require treatment with prohibited concomitant medication(s) or have received a prohibited concomitant medication within specified time frames prior to the first dose of study medication, including topical treatments that could affect AD
  • Pregnant or breastfeeding women or sexually-active women of who are unwilling to use
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    PF-04965842 200 mg

    Drug: PF-04965842 200 mg

  • Experimental
    PF-04965842 100 mg

    Drug: PF-04965842 100 mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • PF-04965842 200 mg administered as two tablets to be taken orally once daily for 12 weeks

  • PF-04965842 100 mg administered as two tablets to be taken orally once daily for 12 weeks

  • DrugPlacebo

    Placebo administered as two tablets to be taken orally once daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Fold-Change From Baseline in Atopic Dermatitis Biomarkers in Lesional and Non-lesional Skin at Week 12

    Mean fold-changes from baseline at Week 12 in the biomarkers for general inflammation (Matrix Metallopeptidase \[MMP\]12), hyperplasia (Keratin \[KRT\]16), Th2 immune response (C-C motif chemokine ligand \[CCL\]17, CCL18, CCL26), and Th22 immune response (S100 calcium binding protein A \[S100A\]8, S100A9, S100A12), in lesional (LS) and non-lesional (NL) skin tissues, respectively. Expression levels from RT-PCR are normalized to the housekeeping gene RPLP0 by negatively transforming the Ct values to -dCt.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Fold-Change From Baseline in Cellular (T-cell and Dendritic Cell) Inflammation Markers at Week 12

    Mean fold-changes from baseline in immunohistochemistry analysis in lesional skin endpoints at Week 12 are presented. Fold-changes are computed by obtaining the antilog of log2 fold-changes, retaining the sign for log2 fold-change.

    Time frame: Baseline, Week 12

  2. Fold-Change From Baseline in Epidermal Hyperplasia Markers in Skin Biopsies and Skin Thickness at Week 12

    Mean fold-changes from baseline in hyperplasia markers in skin biopsies at Week 12 are presented. Fold-changes are computed by obtaining the antilog of log2 fold-changes, retaining the sign for log2 fold-change.

    Time frame: Baseline, Week 12

  3. Fold-Change From Baseline in Blood Biomarkers for Inflammation and Immune Response at Week 12

    OLINK Proteomics Microassay was used to analyze biomarkers in serum to assess the effect of abrocitinib on the blood biomarkers. Mean fold-changes at Week 12 from baseline are listed. Baseline is defined as the last observation on or prior to day of first dose (Day 1).

    Time frame: Baseline, Week 12

  4. Percent-Change From Baseline in T-cell Lymphocyte Subset Populations at Week 12

    Mean percent changes from baseline at Week 12 in T-cell lymphocyte subset populations (CD3+ T cells, CD4+ T cells, CD8+ T cells, NK cells, B cells) are presented. Baseline is defined as the last observation on or prior to day of first dose (Day 1).

    Time frame: Baseline, Week 12

  5. Response Based on at Least 4 Points Improvement in the Severity of Peak Pruritus Numerical Rating Scale (NRS) From Baseline and Changes From Baseline in Immunohistochemistry (IHC) and Gene Expression Biomarkers in Lesional Skin

    PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Participants who withdrew from the study were counted as non-responder. Spearman correlation coefficient was calculated to assess the relationship between PP-NRS CFB and fold CFB of IHC and gene expression biomarkers.

    Time frame: Baseline, Week 12

  6. Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear' or 'Almost Clear' and >=2 Points Improvement From Baseline at Week 2, 4, 8 and 12

    The IGA of AD is scored on a 5-point scale (0-4), reflecting a global consideration of the erythema, induration and scaling. The overall severity of AD was assessed according to the 5-point scale: 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, and 4=Severe. Participants who withdrew from the study were counted as non-responder.

    Time frame: Baseline, Weeks 2, 4, 8, and 12

  7. Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response ≥ 75% Improvement From Baseline Week 2, 4, 8 and 12

    The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of body surface area (BSA) affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.

    Time frame: Baseline, Week 2, 4, 8, and 12

  8. Percentage of Participants With >=4 Points at Baseline and Achieving >=4 Points Improvement From Baseline in Numeric Rating Scale for Severity of Pruritus (PP-NRS) at Weeks 2, 4, 8 and 12

    PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Higher scores indicated worse itch. Participants who withdrew from the study were counted as non-responder.

    Time frame: Baseline, Week 2, 4, 8, 12

  9. Percentage of Participants Achieving EASI Response ≥ 90% Improvement From Baseline at Week 2, 4, 8 and 12

    The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.

    Time frame: Baseline to Week 2, 4, 8 and 12

  10. Percentage of Participants Achieving EASI Response ≥ 50% Improvement From Baseline at Week 2, 4, 8 and 12

    The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.

    Time frame: Baseline to Week 2, 4, 8 and 12

  11. Percent Change From Baseline in Percentage Body Surface Area (BSA) at Week 2, 4, 8 and 12

    BSA efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. The percentage BSA ranges from 0 to 100, with higher scores representing greater severity of AD. Since the scalp, palms, and soles were excluded from the BSA (efficacy) assessment, the maximum possible percentage BSA was less than 100.

    Time frame: Baseline and Week 2, 4, 8 and 12

  12. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs that occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.

    Time frame: Baseline to 16 weeks

  13. Number of Participants With Serious Adverse Events (SAEs)

    A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. Treatment-related SAEs were determined by the investigator.

    Time frame: Baseline to 16 weeks

  14. Number of Participants Who Discontinued From the Study Due to TEAEs

    An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs that occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.

    Time frame: Baseline to 16 weeks

  15. Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)

    Laboratory tests included hematology (including coagulation panel), clinical chemistry, lipid profile panel, and routine urinalysis. LLN is lower limit of normal. ULN is upper limit of normal.

    Time frame: Baseline to 16 weeks

Other outcomes

  1. Change From Baseline in Erythrocytes at Week 2, 4, 8 and 12

    Clinical laboratory tests including red blood cell (erythrocytes) were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.

    Time frame: Baseline and Week 2, 4, 8 and 12

  2. Change From Baseline in Reticulocytes at Week 2, 4, 8 and 12

    Clinical laboratory tests including reticulocytes were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.

    Time frame: Baseline and Week 2, 4, 8 and 12

  3. Change From Baseline in Platelet Counts at Week 2, 4, 8 and 12

    Clinical laboratory tests including platelet counts were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.

    Time frame: Baseline and Week 2, 4, 8 and 12

  4. Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) at Week 2, 4, 8 and 12

    Clinical laboratory tests including hs-CRP were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.

    Time frame: Baseline and Week 2, 4, 8 and 12

  5. Change From Baseline in Interleukin 6 at Week 2, 4, 8 and 12

    Clinical laboratory tests including interleukin were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.

    Time frame: Baseline and Week 2, 4, 8 and 12

  6. Change From Baseline in Erythropoietin at Week 2, 4, 8 and 12

    Clinical laboratory tests including erythropoietin were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.

    Time frame: Baseline and Week 2, 4, 8 and 12

  7. Change From Baseline in Thrombopoietin at Week 2, 4, 8 and 12

    Clinical laboratory tests including thrombopoietin were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.

    Time frame: Baseline and Week 2, 4, 8 and 12

  8. Change From Baseline in Night Time Itch Scale Score at Week 2, 4, 8 and 12

    The severity and frequency of itch (pruritus) during the night due to AD was assessed using the Night Time Itch Scale Score. Participants assessed their worst itching due to AD during their most recent night's sleep on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Higher scores indicated worse itch. The frequency of itch was assessed using a 5-point qualitative scale, with responses including "Never", "Rarely", "Sometimes", "Often" and "Almost Always".

    Time frame: Baseline and Week 2, 4, 8 and 12

  9. Plasma PF-04965842 Concentration

    Pharmacokinetic (PK) samples were collected at Week 4 and 12 for measurement of plasma concentration of PF-04965842.

    Time frame: Day 29 Hour 0 (prior to dosing) and 30 miniute post-dose, Day 85 30 minute and Hour 4 post-dose

  10. Plasma PF-06471658 (M1) Concentration

    PK samples were collected at Week 4 and 12 for measurement of plasma concentration of abrocitinib's metabolite PF-06471658 (M1).

    Time frame: Day 29 Hour 0 (prior to dosing) and 30 miniute post-dose, Day 85 30 minute and Hour 4 post-dose

  11. Plasma PF-07055087 (M2) Concentration

    PK samples were collected at Week 4 and 12 for measurement of plasma concentration of abrocitinib's metabolite PF-07055087 (M2).

    Time frame: Day 29 Hour 0 (prior to dosing) and 30 miniute post-dose, Day 85 30 minute and Hour 4 post-dose

  12. Plasma PF-07054874 (M4) Concentration

    PK samples were collected at Week 4 and 12 for measurement of plasma concentration of abrocitinib's metabolites PF-07054874 (M4).

    Time frame: Day 29 Hour 0 (prior to dosing) and 30 miniute post-dose, Day 85 30 minute and Hour 4 post-dose

07

Results

Posted Feb 8, 2023

Participant flow

A total of 46 adult participants with moderate-to-severe atopic dermatitis (AD) were randomized to the study and received study intervention, including 16 participants in the abrocitinib (PF-04965842) 100 mg once daily (QD) group, 14 participants in the abrocitinib 200 mg QD group, and 16 participants in the placebo group.

Participant flow — Overall Study
MilestoneAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
Started161416
Completed141314
Not completed212
Withdrew: Adverse event212

Outcome measures

PrimaryFold-Change From Baseline in Atopic Dermatitis Biomarkers in Lesional and Non-lesional Skin at Week 12

Mean fold-changes from baseline at Week 12 in the biomarkers for general inflammation (Matrix Metallopeptidase \[MMP\]12), hyperplasia (Keratin \[KRT\]16), Th2 immune response (C-C motif chemokine ligand \[CCL\]17, CCL18, CCL26), and Th22 immune response (S100 calcium binding protein A \[S100A\]8, S100A9, S100A12), in lesional (LS) and non-lesional (NL) skin tissues, respectively. Expression levels from RT-PCR are normalized to the housekeeping gene RPLP0 by negatively transforming the Ct values to -dCt.

Time frame:
Baseline, Week 12
Reported as:
Mean · Fold change
Fold-Change From Baseline in Atopic Dermatitis Biomarkers in Lesional and Non-lesional Skin at Week 12
Fold changeAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
CCL17 (LS)-5.896 ± 16.0867-15.604 ± 38.5469-0.729 ± 4.0821
CCL17 (NL)-0.506 ± 7.5268-3.150 ± 2.6554-3.354 ± 7.6800
CCL18 (LS)-11.600 ± 18.9748-24.558 ± 46.2466-1.096 ± 3.6800
CCL18 (NL)-18.307 ± 24.0808-12.328 ± 13.3680-0.761 ± 2.8516
CCL26 (LS)-3.886 ± 9.6426-0.464 ± 5.2150-0.205 ± 1.7928
CCL26 (NL)-3.619 ± 2.1674-4.369 ± 8.06210.026 ± 2.0613
KRT16 (LS)-24.604 ± 47.3896-53.285 ± 70.6935-1.898 ± 19.4730
KRT16 (NL)-3.179 ± 6.2518-2.947 ± 1.4188-2.674 ± 7.2836
MMP-12 (LS)-44.200 ± 123.0708-306.161 ± 503.8312-0.184 ± 3.0962
MMP-12 (NL)-20.822 ± 31.5640-27.523 ± 16.5608-1.897 ± 3.6968
S100A12 (LS)-13.931 ± 23.9740-1322.88 ± 4594.1875.994 ± 57.0002
S100A12 (NL)4.052 ± 0.4124-4.300 ± 4.2217-14.200 ± 21.2222
S100A8 (LS)-76.158 ± 181.1015-312.430 ± 395.07961.213 ± 31.0236
S100A8 (NL)-3.797 ± 3.9226-14.249 ± 13.2540-8.394 ± 10.7181
S100A9 (LS)-52.132 ± 113.0256-304.023 ± 376.0106-2.136 ± 17.2326
S100A9 (NL)-2.781 ± 5.6012-34.776 ± 42.4019-7.368 ± 10.0856
SecondaryFold-Change From Baseline in Cellular (T-cell and Dendritic Cell) Inflammation Markers at Week 12

Mean fold-changes from baseline in immunohistochemistry analysis in lesional skin endpoints at Week 12 are presented. Fold-changes are computed by obtaining the antilog of log2 fold-changes, retaining the sign for log2 fold-change.

Time frame:
Baseline, Week 12
Reported as:
Mean · Fold change
Fold-Change From Baseline in Cellular (T-cell and Dendritic Cell) Inflammation Markers at Week 12
Fold changeAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
CD11C-1.622 (-2.404 to -1.094)-2.460 (-3.719 to -1.627)-1.326 (-1.968 to 1.118)
CD3-1.952 (-2.979 to -1.279)-2.371 (-3.696 to -1.521)-1.054 (-1.610 to 1.450)
Fc Epsilon R1-1.610 (-2.276 to -1.140)-2.088 (-3.003 to -1.453)1.092 (-1.295 to 1.545)
Macrophage mannose receptor 1-1.249 (-1.538 to -1.015)-1.835 (-2.282 to -1.476)-1.155 (-1.422 to 1.066)
SecondaryFold-Change From Baseline in Epidermal Hyperplasia Markers in Skin Biopsies and Skin Thickness at Week 12

Mean fold-changes from baseline in hyperplasia markers in skin biopsies at Week 12 are presented. Fold-changes are computed by obtaining the antilog of log2 fold-changes, retaining the sign for log2 fold-change.

Time frame:
Baseline, Week 12
Reported as:
Mean · Fold change
Fold-Change From Baseline in Epidermal Hyperplasia Markers in Skin Biopsies and Skin Thickness at Week 12
Fold changeAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
Ki-67-1.638 (-2.859 to 1.066)-1.911 (-3.432 to -1.064)-1.153 (-2.016 to 1.516)
Thickness-1.310 (-1.735 to 1.010)-1.508 (-2.024 to -1.123)-1.185 (-1.570 to 1.118)
SecondaryFold-Change From Baseline in Blood Biomarkers for Inflammation and Immune Response at Week 12

OLINK Proteomics Microassay was used to analyze biomarkers in serum to assess the effect of abrocitinib on the blood biomarkers. Mean fold-changes at Week 12 from baseline are listed. Baseline is defined as the last observation on or prior to day of first dose (Day 1).

Time frame:
Baseline, Week 12
Reported as:
Mean · Fold change
Fold-Change From Baseline in Blood Biomarkers for Inflammation and Immune Response at Week 12
Fold changeAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
C-C motif chemokine ligand 23 (CCL23)-0.247 ± 0.3367-0.519 ± 0.3958-0.245 ± 0.4302
C-C motif chemokine ligand 17 (CCL17)-0.619 ± 0.8281-0.880 ± 1.06300.108 ± 0.8299
Selectin E (SELE)-0.520 ± 0.6198-0.717 ± 0.6172-0.170 ± 0.3571
Integrin subunit beta 2 (ITGB2)-0.280 ± 0.3067-0.574 ± 0.26490.058 ± 0.1877
Platelet-derived growth factor (PDGF) subunit B-0.057 ± 0.2185-0.182 ± 0.35610.085 ± 0.2916
PDGF subunit A-0.360 ± 0.3354-0.590 ± 0.3884-0.039 ± 0.1802
Linker for activation of T cells (LAT)-0.127 ± 0.4281-0.322 ± 0.3329-0.169 ± 0.3493
C-C motif chemokine ligand 24 (CCL24)-0.283 ± 0.5321-0.342 ± 0.2439-0.191 ± 0.2425
Lipoprotein lipase (LPL)-0.037 ± 0.59060.281 ± 0.7465-0.224 ± 0.7340
Interferon (IFN)-gamma0.264 ± 1.23820.903 ± 1.95800.763 ± 1.1019
Interleukin 2 receptor subunit alpha (IL2-RA)-0.852 ± 0.6237-0.921 ± 0.4530-0.219 ± 0.3161
Interleukin (IL)-1 alpha0.118 ± 0.4804-0.114 ± 0.25270.046 ± 0.3275
C-C motif chemokine ligand 25 (CCL25)0.229 ± 0.32990.324 ± 0.43510.149 ± 0.2235
C-C motif chemokine ligand 28 (CCL28)0.014 ± 0.24520.108 ± 0.29320.011 ± 0.2962
C-C motif chemokine ligand 20 (CCL20)-0.465 ± 1.19050.111 ± 0.8023-0.333 ± 0.6612
C-C motif chemokine ligand 19 (CCL19)-0.653 ± 0.6620-1.217 ± 0.9084-0.012 ± 0.5347
C-C motif chemokine ligand 16 (CCL16)-0.258 ± 0.2716-0.313 ± 0.1866-0.103 ± 0.2040
C-C motif chemokine ligand 11 (CCL11)0.030 ± 0.26170.109 ± 0.28910.060 ± 0.2005
MMP-12-0.554 ± 0.9534-0.756 ± 0.6576-0.631 ± 0.9298
Tumor necrosis factor receptor superfamily member 9 (TNFRSF9)-0.437 ± 0.3796-0.608 ± 0.2665-0.136 ± 0.2562
Tumor necrosis factor receptor superfamily member 12A (TNFRSF12A)-0.143 ± 0.3348-0.048 ± 0.3744-0.078 ± 0.4294
Matrix metalloproteinase-1 (MMP-1)-0.118 ± 0.15460.004 ± 0.2445-0.002 ± 0.1309
Interleukin 20 receptor subunit alpha (IL-20RA)0.089 ± 0.2394-0.111 ± 0.2573-0.040 ± 0.2018
IL-18-0.488 ± 0.4737-0.578 ± 0.3460-0.182 ± 0.4037
IL-16-0.512 ± 0.5606-0.697 ± 0.5642-0.222 ± 0.5656
IL-12-0.548 ± 0.5020-0.628 ± 0.3935-0.141 ± 0.3341
IL-12B-0.560 ± 0.4540-0.637 ± 0.3808-0.059 ± 0.3230
IL-17C-0.250 ± 1.22650.136 ± 0.5533-0.784 ± 1.0808
IL-7-0.082 ± 0.4541-0.425 ± 0.5173-0.020 ± 0.5239
IL-27-0.099 ± 0.1617-0.177 ± 0.2611-0.073 ± 0.2250
IL-13-0.230 ± 0.4810-0.490 ± 0.6399-0.213 ± 0.6765
IL-17D0.057 ± 0.3222-0.222 ± 0.2921-0.105 ± 0.2420
IL-20-0.155 ± 0.2843-0.171 ± 0.2315-0.137 ± 0.3877
IL-4-0.130 ± 0.6704-0.308 ± 0.5324-0.128 ± 0.3287
IL-4RA-0.075 ± 0.2436-0.619 ± 0.7577-0.340 ± 0.5764
IL-20.005 ± 0.1927-0.069 ± 0.23450.050 ± 0.3024
IL-80.080 ± 0.84630.090 ± 0.80620.152 ± 0.9180
IL-50.049 ± 0.2578-0.164 ± 0.3214-0.020 ± 0.3306
IL-6-0.086 ± 0.95600.150 ± 1.4005-0.228 ± 1.1986
IL-10-0.180 ± 0.4616-0.087 ± 0.4255-0.182 ± 0.6735
IL-330.022 ± 0.2275-0.116 ± 0.2353-0.138 ± 0.2815
Cluster of differentiation (CD) 5-0.373 ± 0.2546-0.405 ± 0.1488-0.064 ± 0.1640
CD4-0.252 ± 0.3139-0.406 ± 0.2184-0.159 ± 0.3220
CD40-0.049 ± 0.1755-0.065 ± 0.30020.039 ± 0.2065
Peptidase Inhibitor 3 (PI3)-0.463 ± 0.6634-0.332 ± 0.6725-0.583 ± 0.8686
Tumor necrosis factor (TNF)-0.328 ± 0.3560-0.227 ± 0.66220.036 ± 0.9515
C-X-C motif chemokine ligand 5 (CXCL5)-0.208 ± 0.2889-0.364 ± 0.40820.068 ± 0.4028
X-C motif chemokine ligand 1 (XCL1)-0.540 ± 0.4209-0.897 ± 0.4253-0.051 ± 0.3028
Thymic stromal lymphopoietin (TSLP)-0.100 ± 0.4871-0.047 ± 0.56100.019 ± 0.4495
CXCL10-0.268 ± 0.9825-0.549 ± 0.95080.363 ± 0.4782
CXCL11-0.399 ± 0.6089-0.695 ± 0.74020.210 ± 0.4335
CXCL9-0.161 ± 0.6273-0.406 ± 0.90610.159 ± 0.5395
CXCL1-0.218 ± 0.3795-0.375 ± 0.3356-0.062 ± 0.3892
CXCL160.031 ± 0.2575-0.033 ± 0.2503-0.011 ± 0.1563
Transforming growth factor (TGF)-beta-1-0.199 ± 0.2853-0.465 ± 0.2884-0.077 ± 0.2521
CCL3-0.168 ± 0.4852-0.171 ± 0.55030.247 ± 0.7508
CX3CL10.346 ± 0.47840.458 ± 0.42690.012 ± 0.2771
CCL4-0.187 ± 0.3558-0.085 ± 0.52110.204 ± 0.4349
Membrane cofactor protein (MCP)-4-0.627 ± 0.7270-0.860 ± 0.6659-0.116 ± 0.6018
MCP-3-0.418 ± 0.8078-0.676 ± 0.5462-0.229 ± 0.7573
MCP-10.053 ± 0.43370.108 ± 0.3722-0.081 ± 0.3836
MCP-2-0.204 ± 0.2714-0.552 ± 0.3286-0.007 ± 0.2398
IL-1ra-0.295 ± 0.4298-0.234 ± 0.6936-0.128 ± 0.6599
IL-6RA-0.162 ± 0.2087-0.274 ± 0.1833-0.022 ± 0.1817
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-0.062 ± 0.2606-0.283 ± 0.29980.086 ± 0.2172
TNF-related weak inducer of apoptosis (TWEAK)-0.057 ± 0.2239-0.157 ± 0.17050.099 ± 0.1471
EN-RAGE-0.175 ± 0.6414-0.383 ± 0.91490.175 ± 0.7755
P-selectin glycoprotein ligand-1 (PSGL-1)-0.025 ± 0.2592-0.087 ± 0.1646-0.012 ± 0.1856
SecondaryPercent-Change From Baseline in T-cell Lymphocyte Subset Populations at Week 12

Mean percent changes from baseline at Week 12 in T-cell lymphocyte subset populations (CD3+ T cells, CD4+ T cells, CD8+ T cells, NK cells, B cells) are presented. Baseline is defined as the last observation on or prior to day of first dose (Day 1).

Time frame:
Baseline, Week 12
Reported as:
Mean · Percent change
Percent-Change From Baseline in T-cell Lymphocyte Subset Populations at Week 12
Percent changeAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
T-cells TBNK Screening (%)-0.2 ± 5.253.6 ± 6.651.7 ± 3.69
T-cells TBNK Screening (absolute)-14.5 ± 19.5014.2 ± 43.431.5 ± 29.10
T lymphocytes CD3+CD4 (%)1.4 ± 7.186.7 ± 11.735.6 ± 7.96
T lymphocytes CD3+CD4 (absolute)-13.2 ± 20.0617.1 ± 41.665.2 ± 29.79
T lymphocytes CD3+CD8 (%)-0.7 ± 12.223.2 ± 10.59-1.6 ± 8.75
T lymphocytes CD3+CD8 (absolute)-15.1 ± 22.1916.2 ± 54.75-1.1 ± 33.17
B-cells TBNK Screening (%)35.5 ± 41.1842.4 ± 37.497.8 ± 23.69
B-cells TBNK Screening (absolute)18.3 ± 52.7155.0 ± 59.817.7 ± 39.19
NK Cells TBNK Screening (%)-27.3 ± 40.12-55.9 ± 24.04-15.2 ± 28.64
NK Cells TBNK Screening (absolute)-40.0 ± 29.41-53.2 ± 26.96-17.9 ± 26.81
SecondaryResponse Based on at Least 4 Points Improvement in the Severity of Peak Pruritus Numerical Rating Scale (NRS) From Baseline and Changes From Baseline in Immunohistochemistry (IHC) and Gene Expression Biomarkers in Lesional Skin

PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Participants who withdrew from the study were counted as non-responder. Spearman correlation coefficient was calculated to assess the relationship between PP-NRS CFB and fold CFB of IHC and gene expression biomarkers.

Time frame:
Baseline, Week 12
Reported as:
Number · Spearman correlation coefficient
Response Based on at Least 4 Points Improvement in the Severity of Peak Pruritus Numerical Rating Scale (NRS) From Baseline and Changes From Baseline in Immunohistochemistry (IHC) and Gene Expression Biomarkers in Lesional Skin
Spearman correlation coefficientAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
CD11C0.2420.4840.439
FC Epsilon R10.4740.4640.238
CD30.4380.4080.151
Macrophage mannose receptor 10.3960.162-0.134
S100A90.3900.5290.334
S100A80.3650.5100.413
KRT160.3130.4860.522
S100A120.2380.4540.460
CCL180.3950.4100.365
SecondaryPercentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear' or 'Almost Clear' and >=2 Points Improvement From Baseline at Week 2, 4, 8 and 12

The IGA of AD is scored on a 5-point scale (0-4), reflecting a global consideration of the erythema, induration and scaling. The overall severity of AD was assessed according to the 5-point scale: 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, and 4=Severe. Participants who withdrew from the study were counted as non-responder.

Time frame:
Baseline, Weeks 2, 4, 8, and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear' or 'Almost Clear' and >=2 Points Improvement From Baseline at Week 2, 4, 8 and 12
Percentage of participantsAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
Week 20 (0.0 to 0.0)7.7 (0.0 to 22.2)0 (0.0 to 0.0)
Week 426.7 (4.3 to 49.0)35.7 (10.6 to 60.8)0 (0.0 to 0.0)
Week 826.7 (4.3 to 49.0)64.3 (39.2 to 89.4)0 (0.0 to 0.0)
Week 1225.0 (3.8 to 46.2)57.1 (31.2 to 83.1)0 (0.0 to 0.0)
SecondaryPercentage of Participants Achieving Eczema Area and Severity Index (EASI) Response ≥ 75% Improvement From Baseline Week 2, 4, 8 and 12

The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of body surface area (BSA) affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.

Time frame:
Baseline, Week 2, 4, 8, and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response ≥ 75% Improvement From Baseline Week 2, 4, 8 and 12
Percentage of participantsAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
Week 26.3 (0.0 to 18.1)38.5 (12.0 to 64.9)0 (0.0 to 0.0)
Week 446.7 (21.4 to 71.9)50.0 (23.8 to 76.2)0 (0.0 to 0.0)
Week 846.7 (21.4 to 71.9)78.6 (57.1 to 100.0)0 (0.0 to 0.0)
Week 1243.8 (19.4 to 68.1)78.6 (57.1 to 100.0)0 (0.0 to 0.0)
SecondaryPercentage of Participants With >=4 Points at Baseline and Achieving >=4 Points Improvement From Baseline in Numeric Rating Scale for Severity of Pruritus (PP-NRS) at Weeks 2, 4, 8 and 12

PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Higher scores indicated worse itch. Participants who withdrew from the study were counted as non-responder.

Time frame:
Baseline, Week 2, 4, 8, 12
Reported as:
Number · Percentage of participants
Percentage of Participants With >=4 Points at Baseline and Achieving >=4 Points Improvement From Baseline in Numeric Rating Scale for Severity of Pruritus (PP-NRS) at Weeks 2, 4, 8 and 12
Percentage of participantsAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
Week 225.0 (3.8 to 46.2)57.1 (31.2 to 83.1)6.3 (0.0 to 18.1)
Week 453.3 (28.1 to 78.6)64.3 (39.2 to 89.4)0 (0.0 to 0.0)
Week 846.7 (21.4 to 71.9)64.3 (39.2 to 89.4)13.3 (0.0 to 30.5)
Week 1235.7 (10.6 to 60.8)64.3 (39.2 to 89.4)6.3 (0.0 to 18.1)
SecondaryPercentage of Participants Achieving EASI Response ≥ 90% Improvement From Baseline at Week 2, 4, 8 and 12

The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.

Time frame:
Baseline to Week 2, 4, 8 and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving EASI Response ≥ 90% Improvement From Baseline at Week 2, 4, 8 and 12
Percentage of participantsAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
Week 20 (0.0 to 0.0)0 (0.0 to 0.0)0 (0.0 to 0.0)
Week 420.0 (0.0 to 40.2)28.6 (4.9 to 52.2)0 (0.0 to 0.0)
Week 820.0 (0.0 to 40.2)57.1 (31.2 to 83.1)0 (0.0 to 0.0)
Week 1237.5 (13.8 to 61.2)50.0 (23.8 to 76.2)0 (0.0 to 0.0)
SecondaryPercentage of Participants Achieving EASI Response ≥ 50% Improvement From Baseline at Week 2, 4, 8 and 12

The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.

Time frame:
Baseline to Week 2, 4, 8 and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving EASI Response ≥ 50% Improvement From Baseline at Week 2, 4, 8 and 12
Percentage of participantsAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
Week 237.5 (13.8 to 61.2)61.5 (35.1 to 88.0)12.5 (0.0 to 28.7)
Week 466.7 (42.8 to 90.5)100.0 (100.0 to 100.0)6.7 (0.0 to 19.3)
Week 853.3 (28.1 to 78.6)100.0 (100.0 to 100.0)6.7 (0.0 to 19.3)
Week 1268.8 (46.0 to 91.5)92.9 (79.4 to 100.0)18.8 (0.0 to 37.9)
SecondaryPercent Change From Baseline in Percentage Body Surface Area (BSA) at Week 2, 4, 8 and 12

BSA efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. The percentage BSA ranges from 0 to 100, with higher scores representing greater severity of AD. Since the scalp, palms, and soles were excluded from the BSA (efficacy) assessment, the maximum possible percentage BSA was less than 100.

Time frame:
Baseline and Week 2, 4, 8 and 12
Reported as:
Mean · Percent change
Percent Change From Baseline in Percentage Body Surface Area (BSA) at Week 2, 4, 8 and 12
Percent changeAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
Week 2-9.6 ± 12.06-17.3 ± 13.784.0 ± 17.25
Week 4-18.7 ± 15.70-23.8 ± 14.192.1 ± 18.35
Week 8-18.7 ± 20.96-28.3 ± 16.840.2 ± 21.59
Week 12-22.0 ± 19.03-28.3 ± 16.95-0.2 ± 23.20
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs that occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.

Time frame:
Baseline to 16 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
All-causality TEAEs1078
Treatment-related TEAEs653
SecondaryNumber of Participants With Serious Adverse Events (SAEs)

A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. Treatment-related SAEs were determined by the investigator.

Time frame:
Baseline to 16 weeks
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
All-causality SAEs001
Treatment-related SAEs001
SecondaryNumber of Participants Who Discontinued From the Study Due to TEAEs

An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs that occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.

Time frame:
Baseline to 16 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued From the Study Due to TEAEs
ParticipantsAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
All-causality TEAEs212
Treatment-related TEAEs211
SecondaryNumber of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)

Laboratory tests included hematology (including coagulation panel), clinical chemistry, lipid profile panel, and routine urinalysis. LLN is lower limit of normal. ULN is upper limit of normal.

Time frame:
Baseline to 16 weeks
Reported as:
Number · Participants
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
ParticipantsAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
Hemoglobin (g/dL) <0.8*LLN100
Hematocrit (%) < 0.8*LLN100
Erythrocytes (10^6/mm3) < 0.8*LLN100
Reticulocytes (10^3/mm3) < 0.5*LLN100
Platelets (10^3/mm3) < 0.5*LLN100
Reticulocytes/Erythrocytes (%) > 1.5*ULN100
Leukocytes (10^3/mm3) < 0.6*LLN100
Lymphocytes (10^3/mm3) < 0.8*LLN200
Lymphocytes/Leukocytes (%) < 0.8*LLN301
Lymphocytes/Leukocytes (%) > 1.2*ULN010
Neutrophils (10^3/mm3) < 0.8*LLN130
Neutrophils/Leukocytes (%) < 0.8*LLN022
Basophils/Leukocytes (%) > 1.2*ULN112
Eosinophils (10^3/mm3) > 1.2*ULN5210
Eosinophils/Leukocytes (%) > 1.2*ULN6210
Monocytes (10^3/mm3) > 1.2x ULN010
Monocytes/Leukocytes (%) > 1.2*ULN130
Prothrombin Time (sec) > 1.1*ULN100
Bilirubin (mg/dL) > 1.5*ULN010
Indirect Bilirubin (mg/dL) > 1.5*ULN010
Aspartate Aminotransferase (U/L) > 3.0*ULN010
Alanine Aminotransferase (U/L) > 3.0*ULN001
Gamma Glutamyl Transferase (U/L) > 3.0*ULN100
Lactate Dehydrogenase (U/L) > 3.0*ULN010
Creatinine (mg/dL) > 1.3*ULN100
Urate (mg/dL) > 1.2*ULN110
Potassium (mEq/L) < 0.9*LLN110
Bicarbonate (mEq/L) > 1.1*ULN010
Creatine Kinase (U/L) > 2.0*ULN132
Cholesterol (mg/dL) > 1.3*ULN001
Ketones ≥ 1020
URINE Protein ≥ 1011
URINE Hemoglobin ≥ 1220
Leukocyte Esterase ≥ 1531
URINE Leukocytes (Scalar) ≥ 20200
Hyaline Casts (/LPF) > 121—
Other pre-specifiedChange From Baseline in Erythrocytes at Week 2, 4, 8 and 12

Clinical laboratory tests including red blood cell (erythrocytes) were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.

Time frame:
Baseline and Week 2, 4, 8 and 12
Reported as:
Mean · 10^6 cells/mm^3
Change From Baseline in Erythrocytes at Week 2, 4, 8 and 12
10^6 cells/mm^3Abrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
Week 2-0.12 ± 0.212-0.21 ± 0.305-0.10 ± 0.242
Week 4-0.16 ± 0.279-0.19 ± 0.266-0.11 ± 0.274
Week 8-0.21 ± 0.301-0.35 ± 0.424-0.02 ± 0.246
Week 12-0.35 ± 0.376-0.47 ± 0.4340.07 ± 0.183
Other pre-specifiedChange From Baseline in Reticulocytes at Week 2, 4, 8 and 12

Clinical laboratory tests including reticulocytes were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.

Time frame:
Baseline and Week 2, 4, 8 and 12
Reported as:
Mean · 10^3 cells/mm^3
Change From Baseline in Reticulocytes at Week 2, 4, 8 and 12
10^3 cells/mm^3Abrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
Week 2-15.43 ± 23.177-25.14 ± 28.0575.33 ± 12.199
Week 4-11.64 ± 27.845-20.86 ± 28.7101.86 ± 16.209
Week 8-9.31 ± 15.997-13.23 ± 18.6820.07 ± 15.345
Week 12-5.07 ± 16.615-7.64 ± 28.1694.33 ± 20.318
Other pre-specifiedChange From Baseline in Platelet Counts at Week 2, 4, 8 and 12

Clinical laboratory tests including platelet counts were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.

Time frame:
Baseline and Week 2, 4, 8 and 12
Reported as:
Mean · 10^3 cells/mm^3
Change From Baseline in Platelet Counts at Week 2, 4, 8 and 12
10^3 cells/mm^3Abrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
Week 2-72.86 ± 93.413-53.23 ± 28.17612.87 ± 51.582
Week 4-89.79 ± 123.180-93.29 ± 36.12311.79 ± 33.025
Week 8-68.15 ± 102.846-71.38 ± 44.9255.79 ± 28.917
Week 12-59.00 ± 104.408-65.79 ± 42.6005.47 ± 34.620
Other pre-specifiedChange From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) at Week 2, 4, 8 and 12

Clinical laboratory tests including hs-CRP were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.

Time frame:
Baseline and Week 2, 4, 8 and 12
Reported as:
Mean · milligrams per deciliter
Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) at Week 2, 4, 8 and 12
milligrams per deciliterAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
Week 2-0.26 ± 0.431-0.07 ± 0.147-0.13 ± 1.538
Week 4-0.24 ± 0.376-0.09 ± 0.217-0.43 ± 1.283
Week 8-0.19 ± 0.2870.03 ± 0.253-0.42 ± 1.182
Week 12-0.15 ± 0.3680.01 ± 0.254-0.40 ± 1.114
Other pre-specifiedChange From Baseline in Interleukin 6 at Week 2, 4, 8 and 12

Clinical laboratory tests including interleukin were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.

Time frame:
Baseline and Week 2, 4, 8 and 12
Reported as:
Mean · picograms per milliliter
Change From Baseline in Interleukin 6 at Week 2, 4, 8 and 12
picograms per milliliterAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
Week 2-0.02 ± 2.732-0.11 ± 7.021-0.44 ± 2.797
Week 40.16 ± 2.533-0.85 ± 5.045-1.83 ± 6.034
Week 80.19 ± 1.3910.15 ± 5.728-3.52 ± 8.228
Week 12-0.23 ± 2.712-0.19 ± 5.305-2.59 ± 6.339
Other pre-specifiedChange From Baseline in Erythropoietin at Week 2, 4, 8 and 12

Clinical laboratory tests including erythropoietin were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.

Time frame:
Baseline and Week 2, 4, 8 and 12
Reported as:
Mean · milliunits per milliliter
Change From Baseline in Erythropoietin at Week 2, 4, 8 and 12
milliunits per milliliterAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
Week 25.38 ± 7.04215.78 ± 29.5960.59 ± 7.412
Week 45.30 ± 6.28614.60 ± 30.4380.35 ± 8.294
Week 87.84 ± 8.30534.12 ± 58.113-1.99 ± 8.101
Week 127.86 ± 15.83154.08 ± 136.613-3.11 ± 6.391
Other pre-specifiedChange From Baseline in Thrombopoietin at Week 2, 4, 8 and 12

Clinical laboratory tests including thrombopoietin were performed at Week 2, 4, 8, and 12 by collecting blood samples and performing the corresponding analysis per the laboratory manual. Fasting was only required prior to labs that included the lipid profile panel.

Time frame:
Baseline and Week 2, 4, 8 and 12
Reported as:
Mean · Picograms per milliliter (pg/mL)
Change From Baseline in Thrombopoietin at Week 2, 4, 8 and 12
Picograms per milliliter (pg/mL)Abrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
Week 238.33 ± 61.92147.64 ± 38.47213.29 ± 31.665
Week 4107.93 ± 274.324103.07 ± 136.964-9.36 ± 31.030
Week 826.93 ± 49.26076.54 ± 116.4334.57 ± 33.073
Week 1230.93 ± 53.72389.57 ± 201.700-7.00 ± 30.166
Other pre-specifiedChange From Baseline in Night Time Itch Scale Score at Week 2, 4, 8 and 12

The severity and frequency of itch (pruritus) during the night due to AD was assessed using the Night Time Itch Scale Score. Participants assessed their worst itching due to AD during their most recent night's sleep on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Higher scores indicated worse itch. The frequency of itch was assessed using a 5-point qualitative scale, with responses including "Never", "Rarely", "Sometimes", "Often" and "Almost Always".

Time frame:
Baseline and Week 2, 4, 8 and 12
Reported as:
Mean · Units on a scale
Change From Baseline in Night Time Itch Scale Score at Week 2, 4, 8 and 12
Units on a scaleAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
NRS01-Severity of Night Time Itch Week 2-2.4 ± 2.16-4.6 ± 2.79-0.3 ± 1.83
NRS01-Severity of Night Time Itch Week 4-4.4 ± 3.38-4.9 ± 3.52-1.1 ± 2.53
NRS01-Severity of Night Time Itch Week 8-3.5 ± 4.14-5.5 ± 3.52-0.8 ± 2.85
NRS01-Severity of Night Time Itch Week 12-3.4 ± 3.80-4.8 ± 3.77-1.1 ± 2.46
NRS01-Frequency of Night Time Itch Week 2-0.8 ± 0.91-2.1 ± 1.14-0.2 ± 1.08
NRS01-Frequency of Night Time Itch Week 4-1.8 ± 1.08-2.5 ± 1.09-0.6 ± 1.12
NRS01-Frequency of Night Time Itch Week 8-1.4 ± 1.35-2.7 ± 1.14-0.6 ± 1.39
NRS01-Frequency of Night Time Itch Week 12-1.2 ± 1.21-2.5 ± 1.45-0.4 ± 1.22
Other pre-specifiedPlasma PF-04965842 Concentration

Pharmacokinetic (PK) samples were collected at Week 4 and 12 for measurement of plasma concentration of PF-04965842.

Time frame:
Day 29 Hour 0 (prior to dosing) and 30 miniute post-dose, Day 85 30 minute and Hour 4 post-dose
Reported as:
Mean · nanogram per milliliter (ng/mL)
Plasma PF-04965842 Concentration
nanogram per milliliter (ng/mL)Abrocitinib 100 mg QDAbrocitinib 200 mg QD
Day 29 Hour 014.77 ± 29.293135.7 ± 272.53
Day 29 30 minute266.6 ± 381.11802.7 ± 1128.2
Day 85 30 minute617.6 ± 588.85792.2 ± 1013.9
Day 85 Hour 4433.0 ± 255.441147 ± 580.56
Other pre-specifiedPlasma PF-06471658 (M1) Concentration

PK samples were collected at Week 4 and 12 for measurement of plasma concentration of abrocitinib's metabolite PF-06471658 (M1).

Time frame:
Day 29 Hour 0 (prior to dosing) and 30 miniute post-dose, Day 85 30 minute and Hour 4 post-dose
Reported as:
Mean · ng/mL
Plasma PF-06471658 (M1) Concentration
ng/mLAbrocitinib 100 mg QDAbrocitinib 200 mg QD
Day 29 Hour 02.588 ± 3.407123.13 ± 47.649
Day 29 30 minute65.82 ± 137.6695.54 ± 108.21
Day 85 30 minute92.51 ± 80.71765.03 ± 51.765
Day 85 Hour 482.84 ± 70.532104.9 ± 80.782
Other pre-specifiedPlasma PF-07055087 (M2) Concentration

PK samples were collected at Week 4 and 12 for measurement of plasma concentration of abrocitinib's metabolite PF-07055087 (M2).

Time frame:
Day 29 Hour 0 (prior to dosing) and 30 miniute post-dose, Day 85 30 minute and Hour 4 post-dose
Reported as:
Mean · ng/mL
Plasma PF-07055087 (M2) Concentration
ng/mLAbrocitinib 100 mg QDAbrocitinib 200 mg QD
Day 29 Hour 09.933 ± 22.62923.86 ± 40.798
Day 29 30 minute42.89 ± 66.78973.84 ± 75.245
Day 85 30 minute77.56 ± 63.48370.58 ± 67.136
Day 85 Hour 4100.0 ± 46.321132.9 ± 69.048
Other pre-specifiedPlasma PF-07054874 (M4) Concentration

PK samples were collected at Week 4 and 12 for measurement of plasma concentration of abrocitinib's metabolites PF-07054874 (M4).

Time frame:
Day 29 Hour 0 (prior to dosing) and 30 miniute post-dose, Day 85 30 minute and Hour 4 post-dose
Reported as:
Mean · ng/mL
Plasma PF-07054874 (M4) Concentration
ng/mLAbrocitinib 100 mg QDAbrocitinib 200 mg QD
Day 29 Hour 016.10 ± 33.53748.43 ± 83.563
Day 29 30 minute63.76 ± 80.663153.4 ± 163.23
Day 85 30 minute149.9 ± 126.33158.2 ± 174.55
Day 85 Hour 4170.4 ± 68.419268.2 ± 173.11

Adverse events

Collected over Baseline up to 16 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abrocitinib 100 mg QD0/16 (0%)0/16 (0%)10/16 (62.5%)
Abrocitinib 200 mg QD0/14 (0%)0/14 (0%)7/14 (50%)
Placebo0/16 (0%)1/16 (6.3%)7/16 (43.8%)
Most frequent serious events
Most frequent serious events
EventAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
Eczema herpeticumInfections and infestations0/160/141/16
Periorbital cellulitisInfections and infestations0/160/141/16
SepsisInfections and infestations0/160/141/16
Most frequent other events
Showing 10 of 32
Most frequent other events
EventAbrocitinib 100 mg QDAbrocitinib 200 mg QDPlacebo
NauseaGastrointestinal disorders3/164/141/16
HeadacheNervous system disorders1/162/140/16
DizzinessNervous system disorders2/161/140/16
Abdominal distensionGastrointestinal disorders0/161/140/16
HaemorrhoidsGastrointestinal disorders0/161/140/16
Rectal haemorrhageGastrointestinal disorders0/161/140/16
FolliculitisInfections and infestations0/161/140/16
Herpes simplexInfections and infestations0/161/140/16
Aspartate aminotransferase increasedInvestigations0/161/140/16
Blood creatine phosphokinase increasedInvestigations0/161/140/16

Baseline characteristics

Baseline analysis population included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the intervention they actually received.

Age, Continuous
Age, Continuous(Years)Abrocitinib 100 mg QDAbrocitinib 200 mg QDPlaceboTotal
Mean46.6 ± 19.4141.4 ± 16.7238.9 ± 15.6442.4 ± 17.28
Sex: Female, Male
Sex: Female, Male(Participants)Abrocitinib 100 mg QDAbrocitinib 200 mg QDPlaceboTotal
Female117321
Male571325
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Abrocitinib 100 mg QDAbrocitinib 200 mg QDPlaceboTotal
Hispanic or Latino3238
Not Hispanic or Latino13121136
Unknown or Not Reported0022
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Abrocitinib 100 mg QDAbrocitinib 200 mg QDPlaceboTotal
White1051126
Black or African American4127
Asian1629
Multiracial0112
Not reported1102
08

Study locations

11 sites
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • Keck School of Medicine of USC - IDS Pharmacy
    Los Angeles, California 90033, United States
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Olympian Clinical Research
    Largo, Florida 33770, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • The Indiana Clinical Trials Center, PC - Dermatology Research
    Plainfield, Indiana 46168, United States
  • Wayne Health - Wayne State Dermatology
    Dearborn, Michigan 48124, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Menter Dermatology Research Institute
    Dallas, Texas 75246, United States
  • Beacon Dermatology
    Calgary, Alberta T3E 0B2, Canada
  • Innovaderm Research, Inc.
    Montreal, Quebec H2X 2V1, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Nov 2021, 16 months.

Results were first posted in Feb 2023, 1 year 2 months after primary completion.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 16 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2019
First posted
Apr 16, 2019
StartActual
Jun 18, 2020
Primary completionActual
Nov 16, 2021
CompletionActual
Nov 16, 2021
Results first posted
Feb 8, 2023
Last update
Feb 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03915496
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 16, 2019
Start date
Jun 18, 2020
Primary completion
Nov 16, 2021
Completion
Nov 16, 2021
Results posted
Feb 8, 2023
Last update
Feb 8, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abrocitinib

Start the discussion